Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

(2022) Hung Fu Tseng et al.   NATURE MEDICINE

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

(2022) Rolando Pajon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

(2022) Peter B. Gilbert et al.   SCIENCE

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

(2022) Matthew Gagne et al.   CELL

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial

(2022) Hana M. El Sahly et al.   JOURNAL OF INFECTIOUS DISEASES

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

(2022) Laurence Chu et al.   NATURE MEDICINE

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity

(2022) Peter V. Markov et al.   NATURE REVIEWS MICROBIOLOGY

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

(2022) Paulina Kaplonek et al.   Science Translational Medicine

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

(2022) Spyros Chalkias et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of antibody immunity to SARS-CoV-2

(2021) Christian Gaebler et al.   NATURE

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

(2021) Mark W. Tenforde et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

(2021) Mark G. Thompson et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

(2021) Angela Choi et al.   NATURE MEDICINE

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

(2021) Mark G. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

(2021) Hana M. El Sahly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

(2021) Amarendra Pegu et al.   SCIENCE

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

(2021) Kathryn M. Hastie et al.   SCIENCE

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

(2021) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Origin and evolution of pathogenic coronaviruses

(2018) Jie Cui et al.   NATURE REVIEWS MICROBIOLOGY